EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

P. W. Hellings; S. Lau; G. K. Scadding; L. Bjermer; V. Backer; A. M. Chaker; D. M. Conti; E. de Corso; Z. Diamant; R. Djukanovic; W. Fokkens; P. Gevaert; C. L. Gray; J. K. Han; L. G. Heaney; H. J. Hoffmann; M. Jesenak; P. Johansen; M. S. Kumaran; M. McDonald; E. Melén; J. Mullol; S. Reitsma; D. Ryan; G. Scadding; P. Schmid-Grendelmeier; T. Teeling; M. Odemyr; U. Wahn

doi:https://doi.org/10.3389/falgy.2023.1236977

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

P. W. Hellings, S. Lau, G. K. Scadding, L. Bjermer, V. Backer, A. M. Chaker, D. M. Conti, E. de Corso, Z. Diamant, R. Djukanovic, W. Fokkens, P. Gevaert, C. L. Gray, J. K. Han, L. G. Heaney, H. J. Hoffmann, M. Jesenak, P. Johansen, M. S. Kumaran, M. McDonaldE. Melén, J. Mullol, S. Reitsma, D. Ryan, G. Scadding, P. Schmid-Grendelmeier, T. Teeling, M. Odemyr, U. Wahn

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.

Original language	English
Article number	1236977
Journal	Frontiers in allergy
Volume	4
DOIs	https://doi.org/10.3389/falgy.2023.1236977
Publication status	Published - 2023

Keywords

EUFOREA
allergen immunotherapy
allergic rhinitis
asthma
paediatrics
patient advisory board
pocket guide
rhinosinusitis

Access to Document

https://doi.org/10.3389/falgy.2023.1236977

Cite this

Hellings, P. W., Lau, S., Scadding, G. K., Bjermer, L., Backer, V., Chaker, A. M., Conti, D. M., de Corso, E., Diamant, Z., Djukanovic, R., Fokkens, W., Gevaert, P., Gray, C. L., Han, J. K., Heaney, L. G., Hoffmann, H. J., Jesenak, M., Johansen, P., Kumaran, M. S., ... Wahn, U. (2023). EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care. Frontiers in allergy, 4, Article 1236977. https://doi.org/10.3389/falgy.2023.1236977

@article{a43802b8cbbf419a82dd2a74b1949687,

title = "EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care",

abstract = "In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.",

keywords = "EUFOREA, allergen immunotherapy, allergic rhinitis, asthma, paediatrics, patient advisory board, pocket guide, rhinosinusitis",

author = "Hellings, {P. W.} and S. Lau and Scadding, {G. K.} and L. Bjermer and V. Backer and Chaker, {A. M.} and Conti, {D. M.} and {de Corso}, E. and Z. Diamant and R. Djukanovic and W. Fokkens and P. Gevaert and Gray, {C. L.} and Han, {J. K.} and Heaney, {L. G.} and Hoffmann, {H. J.} and M. Jesenak and P. Johansen and Kumaran, {M. S.} and M. McDonald and E. Mel{\'e}n and J. Mullol and S. Reitsma and D. Ryan and G. Scadding and P. Schmid-Grendelmeier and T. Teeling and M. Odemyr and U. Wahn",

note = "Funding Information: The EUFOREA Summit was organized in Brussels in March 2023 with support of corporate partners of EUFOREA GSK and Sanofi/Regeneron. Publisher Copyright: 2023 Hellings, Lau, Scadding, Bjermer, Backer, Chaker, Conti, De Corso, Diamant, Djukanovic, Fokkens, Gevaert, Gray, Han, Heaney, Hoffmann, Jesenak, Johansen, Kumaran, McDonald, Mel{\'e}n, Mullol, Reitsma, Ryan, Scadding, Schmid-Grendelmeier, Teeling, Odemyr and Wahn.",

year = "2023",

doi = "https://doi.org/10.3389/falgy.2023.1236977",

language = "English",

volume = "4",

journal = "Frontiers in allergy",

issn = "2673-6101",

publisher = "Frontiers Media S.A.",

}

Hellings, PW, Lau, S, Scadding, GK, Bjermer, L, Backer, V, Chaker, AM, Conti, DM, de Corso, E, Diamant, Z, Djukanovic, R, Fokkens, W, Gevaert, P, Gray, CL, Han, JK, Heaney, LG, Hoffmann, HJ, Jesenak, M, Johansen, P, Kumaran, MS, McDonald, M, Melén, E, Mullol, J, Reitsma, S, Ryan, D, Scadding, G, Schmid-Grendelmeier, P, Teeling, T, Odemyr, M & Wahn, U 2023, 'EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care', Frontiers in allergy, vol. 4, 1236977. https://doi.org/10.3389/falgy.2023.1236977

TY - JOUR

T1 - EUFOREA summit in Brussels 2023

T2 - inspiring the future of allergy & respiratory care

AU - Hellings, P. W.

AU - Lau, S.

AU - Scadding, G. K.

AU - Bjermer, L.

AU - Backer, V.

AU - Chaker, A. M.

AU - Conti, D. M.

AU - de Corso, E.

AU - Diamant, Z.

AU - Djukanovic, R.

AU - Fokkens, W.

AU - Gevaert, P.

AU - Gray, C. L.

AU - Han, J. K.

AU - Heaney, L. G.

AU - Hoffmann, H. J.

AU - Jesenak, M.

AU - Johansen, P.

AU - Kumaran, M. S.

AU - McDonald, M.

AU - Melén, E.

AU - Mullol, J.

AU - Reitsma, S.

AU - Ryan, D.

AU - Scadding, G.

AU - Schmid-Grendelmeier, P.

AU - Teeling, T.

AU - Odemyr, M.

AU - Wahn, U.

N1 - Funding Information: The EUFOREA Summit was organized in Brussels in March 2023 with support of corporate partners of EUFOREA GSK and Sanofi/Regeneron. Publisher Copyright: 2023 Hellings, Lau, Scadding, Bjermer, Backer, Chaker, Conti, De Corso, Diamant, Djukanovic, Fokkens, Gevaert, Gray, Han, Heaney, Hoffmann, Jesenak, Johansen, Kumaran, McDonald, Melén, Mullol, Reitsma, Ryan, Scadding, Schmid-Grendelmeier, Teeling, Odemyr and Wahn.

PY - 2023

Y1 - 2023

N2 - In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.

AB - In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.

KW - EUFOREA

KW - allergen immunotherapy

KW - allergic rhinitis

KW - asthma

KW - paediatrics

KW - patient advisory board

KW - pocket guide

KW - rhinosinusitis

UR - http://www.scopus.com/inward/record.url?scp=85167606641&partnerID=8YFLogxK

U2 - https://doi.org/10.3389/falgy.2023.1236977

DO - https://doi.org/10.3389/falgy.2023.1236977

M3 - Article

C2 - 37577332

SN - 2673-6101

VL - 4

JO - Frontiers in allergy

JF - Frontiers in allergy

M1 - 1236977

ER -

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

Abstract

Keywords

Access to Document

Other files and links

Cite this